Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Earlier evidence for retatrutide comes from a Phase 2 trial in NEJM in 2023, which reported 24.2% weight loss at 12 mg over 48 weeks
The Rosenstock Phase 2 in type 2 diabetes assigned 281 adults T2D, BMI 25 to retatrutide across multiple dose tiers, an active GLP-1 mono-agonist comparator, or placebo
Is a Retatrutide 4mg dose considered a low, mid, or higher research level
We don't do walk-in IV drips off a general menu
D., Skwiat, T
These innovations aim to improve patient adherence and convenience, which could increase clinical value to patients
US$ 27.02
US$ 24.21
US$ 23.24
